B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.


Journal

Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199

Informations de publication

Date de publication:
08 07 2019
Historique:
received: 28 07 2018
revised: 14 04 2019
pubmed: 28 6 2019
medline: 21 7 2020
entrez: 28 6 2019
Statut: ppublish

Résumé

What are the effects of B lymphocyte inactivation or depletion on the progression of endometriosis? Skewing activated B cells toward regulatory B cells (Bregs) by Bruton's tyrosine kinase (Btk) inhibition using Ibrutinib prevents endometriosis progression in mice while B cell depletion using an anti-CD20 antibody has no effect. A polyclonal activation of B cells and the presence of anti-endometrial autoantibodies have been described in a large proportion of women with endometriosis though their exact role in the disease mechanisms remains unclear. This study included comparison of endometriosis progression for 21 days in control mice versus animals treated with the anti-CD20 depleting antibody or with the Btk inhibitor Ibrutinib that prevents B cell activation. After syngeneic endometrial transplantation, murine endometriotic lesions were compared between treated and control mice using volume, weight, ultrasonography, histology and target genes expression in lesions. Phenotyping of activated and regulatory B cells, T lymphocytes and macrophages was performed by flow cytometry on isolated spleen and peritoneal cells. Cytokines were assayed by ELISA. Btk inhibitor Ibrutinib prevented lesion growth, reduced mRNA expression of cyclooxygenase-2, alpha smooth muscle actin and type I collagen in the lesions and skewed activated B cells toward Bregs in the spleen and peritoneal cavity of mice with endometriosis. In addition, the number of M2 macrophages decreased in the peritoneal cavity of Ibrutinib-treated mice compared to anti-CD20 and control mice. Depletion of B cells using an anti-CD20 antibody had no effect on activity and growth of endometriotic lesions and neither on the macrophages, compared to control mice. N/A. It is still unclear whether B cell depletion by the anti-CD20 or inactivation by Ibrutinib can prevent establishment and/or progression of endometriosis in humans. Further investigation may contribute to clarifying the role of B cell subsets in human endometriosis. This research was supported by a grant of Institut National de la Santé et de la Recherche Médicale and Paris Descartes University. None of the authors has any conflict of interest to disclose.

Identifiants

pubmed: 31247078
pii: 5523893
doi: 10.1093/humrep/dez071
doi:

Substances chimiques

Cytokines 0
Piperidines 0
Pyrazoles 0
Pyrimidines 0
ibrutinib 1X70OSD4VX
Agammaglobulinaemia Tyrosine Kinase EC 2.7.10.2
Adenine JAC85A2161

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1225-1234

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

L G C Riccio (LGC)

Département 'Développement, Reproduction et Cancer', Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Université Paris Descartes, Sorbonne Paris Cité Paris, France.
Faculté de Médecine, Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
Faculty of Medicine, Endometriosis Division, Obstetrics and Gynecology Department, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, Cerqueira César 05403-000, São Paulo, Brazil.

M Jeljeli (M)

Département 'Développement, Reproduction et Cancer', Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Université Paris Descartes, Sorbonne Paris Cité Paris, France.
Faculté de Médecine, Sorbonne Paris Cité, Université Paris Descartes, Paris, France.

P Santulli (P)

Département 'Développement, Reproduction et Cancer', Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Université Paris Descartes, Sorbonne Paris Cité Paris, France.
Faculté de Médecine, Sorbonne Paris Cité, Université Paris Descartes, Paris, France.

S Chouzenoux (S)

Département 'Développement, Reproduction et Cancer', Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Université Paris Descartes, Sorbonne Paris Cité Paris, France.

L Doridot (L)

Département 'Développement, Reproduction et Cancer', Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Université Paris Descartes, Sorbonne Paris Cité Paris, France.

C Nicco (C)

Département 'Développement, Reproduction et Cancer', Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Université Paris Descartes, Sorbonne Paris Cité Paris, France.

F M Reis (FM)

Département 'Développement, Reproduction et Cancer', Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Université Paris Descartes, Sorbonne Paris Cité Paris, France.

M S Abrão (MS)

Faculty of Medicine, Endometriosis Division, Obstetrics and Gynecology Department, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, Cerqueira César 05403-000, São Paulo, Brazil.

C Chapron (C)

Département 'Développement, Reproduction et Cancer', Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Université Paris Descartes, Sorbonne Paris Cité Paris, France.
Département de Gynécologie Obstétrique II et Médecine de la Reproduction, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire Cochin, Paris, France.

F Batteux (F)

Département 'Développement, Reproduction et Cancer', Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Université Paris Descartes, Sorbonne Paris Cité Paris, France.
Service d'Immunologie Biologique, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire Cochin, Paris, France.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH